|
|
130 Waverly Street
Cambridge, MA 02139 USA
phone:(617) 444-6100
fax:+44 (0) 1235 835 880
|
|
| Symbol |
VRTX |
| Exchange |
NASDAQ |
| Founded |
1989 |
| Employees |
720 |
|
|
| www.vrtx.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Treatment of viral diseases, inflammation, autoimmune and genetic disorders. |
|
| Management |
| Ian F. Smith, Executive Vice President & Chief Financial Office; Matthew W. Emmens, Chairman, President and CEO; Peter Mueller, Executive Vice President, Global Research and Development, and Chief Scientific Officer; Nancy J. Wysenski, Executive Vice President and Chief Commercial Officer; Kenneth S. Boger, Senior Vice President and General Counsel |
| |
|
|
|
|
|
|
|
| Keywords |
| cystic, fibrosis, tuberculosis, huntington�s, therapies |
|
|
|
| Description |
|
It develops and commercializes novel, small-molecule drugs that address significant markets with major unmet medical needs, including the treatment of viral diseases, cancer, autoimmune and inflammatory diseases, neurological disorders and genetic diseases. |
|
| Technology / Differentiation |
| In drug discovery, a variety of assays may be performed to measure the biological or pharmacological potency of candidate compounds in order to select the best molecules for more advanced testing. We use modern cell biology, enzymology, and screening techniques to develop high-throughput assays that provide high-quality information to support drug discovery. Many of these assays are built upon a number of gene reporter technologies such as green fluorescent protein and beta lactamase. We also utilize our assay capabilities to develop novel proprietary in vitro assays to rapidly establish ADME/toxicology profiles for compounds in our screening library. |
|
|
| Funding |
| As of December 31, 2004, the Company has $392 million in cash and cash equivalents to fund the discovery and development of its drug candidates, and the Company has significant collaborations with a number of pharmaceutical companies and disease foundations including GlaxoSmithKline, Novartis, Merck, Cystic Fibrosis Foundation Therapeutics, Inc., Mitsubishi Pharma Corp., Kissei, and Schering AG. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
